Patients with MMP-1(-1607G) polymorphism are more vulnerable to more extensive lung fibrosis 1 year after anti-tuberculosis treatment, which may be related to increased MMP-1 activity, leading to enhanced destruction of the matrix with subsequent fibrosis [10]. This evidence concerns the gene MMP1 and pulmonary fibrosis.